Alterome Therapeutics Secures $132M to Drive Precision Oncology Pipeline
April 9, 2024, 9:34 pm
Alterome Therapeutics, a San Diego-based biopharmaceutical company, has successfully completed a $132M Series B funding round. The funding, led by Goldman Sachs Alternatives, will propel the advancement of the company's pipeline programs into clinical trials.
Alterome Therapeutics, under the leadership of CEO Eric Murphy, specializes in developing alteration-specific therapeutics for cancer treatment. Their innovative Kraken platform utilizes structure-guided machine learning to discover precision, small molecule therapies targeting validated oncogenic drivers.
The company's pipeline includes a highly specific AKT1 E17K inhibitor and a KRAS selective inhibitor, designed to target cancer cells while minimizing harm to normal cells. These programs are set to enter clinical testing within the next year, offering hope to patients with limited treatment options.
With a strong investor lineup including Canaan Partners, Invus, and Digitalis Ventures, Alterome Therapeutics is poised to make significant strides in the field of precision oncology. Their commitment to mutation-selective and isoform-selective approaches demonstrates a dedication to enhancing therapeutic safety profiles and maximizing the inhibition of key cancer drivers.
As Alterome Therapeutics continues to push the boundaries of cancer treatment, their recent funding success marks a significant milestone in their mission to revolutionize precision oncology. Watch out for this company as they pave the way for innovative therapies in the fight against cancer.
Alterome Therapeutics, under the leadership of CEO Eric Murphy, specializes in developing alteration-specific therapeutics for cancer treatment. Their innovative Kraken platform utilizes structure-guided machine learning to discover precision, small molecule therapies targeting validated oncogenic drivers.
The company's pipeline includes a highly specific AKT1 E17K inhibitor and a KRAS selective inhibitor, designed to target cancer cells while minimizing harm to normal cells. These programs are set to enter clinical testing within the next year, offering hope to patients with limited treatment options.
With a strong investor lineup including Canaan Partners, Invus, and Digitalis Ventures, Alterome Therapeutics is poised to make significant strides in the field of precision oncology. Their commitment to mutation-selective and isoform-selective approaches demonstrates a dedication to enhancing therapeutic safety profiles and maximizing the inhibition of key cancer drivers.
As Alterome Therapeutics continues to push the boundaries of cancer treatment, their recent funding success marks a significant milestone in their mission to revolutionize precision oncology. Watch out for this company as they pave the way for innovative therapies in the fight against cancer.